Site-Agnostic Cancer Drugs: HTAs Will Need Post-Approval Data
Early Scientific Advice From HTA Bodies Also Recommended
With histology-independent cancer drugs such as Vitrakvi coming to market, a new paper explores how to address the challenges in assessing the clinical and cost effectiveness of these new types of treatments.
